| __timestamp | Novo Nordisk A/S | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 14562000000 | 94103000 |
| Thursday, January 1, 2015 | 16188000000 | 146194000 |
| Friday, January 1, 2016 | 17183000000 | 130000 |
| Sunday, January 1, 2017 | 17632000000 | 7353000 |
| Monday, January 1, 2018 | 17617000000 | 34193000 |
| Tuesday, January 1, 2019 | 20088000000 | 56586000 |
| Wednesday, January 1, 2020 | 20932000000 | 63382000 |
| Friday, January 1, 2021 | 23658000000 | 97049000 |
| Saturday, January 1, 2022 | 28448000000 | 139989000 |
| Sunday, January 1, 2023 | 35765000000 | 150343000 |
| Monday, January 1, 2024 | 44522000000 |
Infusing magic into the data realm
In the ever-evolving landscape of biopharmaceuticals, Novo Nordisk A/S and Sarepta Therapeutics, Inc. present a fascinating study in contrasts. Over the past decade, Novo Nordisk has seen its cost of revenue soar by approximately 145%, from 2014 to 2023, reflecting its expansive growth and market dominance. In stark contrast, Sarepta Therapeutics, while experiencing fluctuations, has maintained a relatively modest cost of revenue, peaking at around $150 million in 2023.
This divergence highlights the differing scales and strategies of these companies. Novo Nordisk, a leader in diabetes care, has consistently expanded its operations, while Sarepta, focused on genetic medicine, navigates the challenges of innovation in a niche market. As we look to the future, these trends offer insights into the strategic priorities and market dynamics shaping the biopharma industry.
Cost of Revenue: Key Insights for Novo Nordisk A/S and Dr. Reddy's Laboratories Limited
Cost of Revenue: Key Insights for Novo Nordisk A/S and MorphoSys AG
Cost Insights: Breaking Down Novo Nordisk A/S and Geron Corporation's Expenses
Comparing Cost of Revenue Efficiency: Novo Nordisk A/S vs BioCryst Pharmaceuticals, Inc.
Cost of Revenue Trends: Novo Nordisk A/S vs Viridian Therapeutics, Inc.
Intra-Cellular Therapies, Inc. vs Sarepta Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Sarepta Therapeutics, Inc. and Jazz Pharmaceuticals plc
Cost of Revenue: Key Insights for Sarepta Therapeutics, Inc. and Lantheus Holdings, Inc.
Cost Insights: Breaking Down Sarepta Therapeutics, Inc. and Corcept Therapeutics Incorporated's Expenses
Comparing Cost of Revenue Efficiency: Sarepta Therapeutics, Inc. vs Alkermes plc
Sarepta Therapeutics, Inc. vs Celldex Therapeutics, Inc.: Efficiency in Cost of Revenue Explored